Immunogen Inc. announced unaudited consolidated earnings results for the second quarter and six months ended December 31, 2011. For the quarter, the company reported total revenues of $7,617,000 against $4,178,000 a year ago. Loss from operations was $12,776,000 against $15,514,000 a year ago. Loss before taxes was $12,753,000 against $14,233,000 a year ago. Net loss was $12,753,000 or $0.17 per basic and diluted share against $14,233,000 or $0.21 per basic and diluted share a year ago. For the six months period, the company reported total revenues of $10,153,000 against $7,589,000 a year ago. Loss from operations was $32,242,000 against $28,892,000 a year ago. Loss before taxes was $32,236,000 against $27,121,000 a year ago. Net loss was $32,236,000 or $0.42 per basic and diluted share against $27,121,000 or $0.40 per basic and diluted share a year ago. Cash used in operations was $24.0 million in the first six months of the fiscal 2012, compared with $18.4 million of cash provided by operations in the same period in the fiscal 2011. Capital expenditures were $0.8 million and $0.9 million for the first six months of the fiscal 2012 and the fiscal 2011, respectively. The company also announced that its financial guidance remains unchanged from that issued in December 2011 when the company entered into a collaboration agreement with Eli Lilly and Company. The company expects its net loss for its fiscal year ending June 30, 2012 to be between $78 million to $82 million. Net cash used in operations is expected to be between $40 million and $45 million.